Novartis agreed to a deal that pays Synnovation roughly $2 billion upfront for a pan‑mutant‑selective PI3Kα inhibitor aimed at breast cancer. The acquisition targets a next‑generation molecule intended to sit alongside or succeed Piqray and shore up Novartis’s position as competitors—including Eli Lilly—advance their own PI3K and metabolic franchises. Company statements indicate Novartis is treating the asset as a strategic bolt‑on to defend and extend its breast‑cancer portfolio amid intensifying competition. The transaction underscores continued industry demand for selective PI3K inhibitors that offer improved safety and efficacy profiles compared with earlier agents.